Wave Life Sciences (WVE) EBITDA Margin (2015 - 2026)
Wave Life Sciences (WVE) posted EBITDA Margin of 81.83% for Q1 2026, up 86.51% on a QoQ basis from 606.49% in Q2 2025, and up 46099.0% year-over-year from N/an in Q1 2025.
Wave Life Sciences (WVE) EBITDA Margin (2015 - 2026) Analysis & Trends
Wave Life Sciences' EBITDA Margin history runs 12 years deep, the most recent figure standing at 81.83% for Q1 2026.
- Quarterly EBITDA Margin rose 46099.0% year-over-year to 81.83% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 259.69% (down 8122.0% YoY) and the FY2025 annual result came in at 504.09%, down 40215.0% from the prior year.
- EBITDA Margin was 81.83% for Q1 2026 at Wave Life Sciences, up from 606.49% in the prior quarter.
- Across five years, EBITDA Margin topped out at 9.03% in Q3 2023 and bottomed at 13648.77% in Q3 2022.
- A 5-year average of 2512.67% and a median of 274.83% in 2024 frame the typical range for EBITDA Margin.
- Annual changes were most pronounced in 2022 — EBITDA Margin plunged 1362789 bps — and 2023, when it surged 1365780 bps.
- Wave Life Sciences' EBITDA Margin stood at 3515.98% in 2022, then soared by 98 bps to 64.3% in 2023, then plunged by 176 bps to 177.72% in 2024, then slumped by 241 bps to 606.49% in 2025, then surged by 87 bps to 81.83% in 2026.
- Business Quant data shows WVE's EBITDA Margin at 81.83% in Q1 2026, 606.49% in Q2 2025, and 542.82% in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 16.51% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 31.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Wave Life Sciences | 1.16 Bn | 612.38 Mn | - | -81.83% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -81.83% |
| Jun 30, 2025 | -606.49% |
| Mar 31, 2025 | -542.82% |
| Jun 30, 2024 | -177.72% |
| Mar 31, 2024 | -274.83% |
| Dec 31, 2023 | -64.30% |
| Sep 30, 2023 | 9.03% |
| Jun 30, 2023 | -106.18% |
| Mar 31, 2023 | -234.24% |
| Dec 31, 2022 | -3,515.98% |
| Sep 30, 2022 | -13,648.77% |
| Jun 30, 2022 | -11,243.73% |
| Mar 31, 2022 | -2,176.80% |
| Dec 31, 2021 | -2,045.89% |
| Sep 30, 2021 | -20.89% |
| Jun 30, 2021 | -1,434.73% |
| Dec 31, 2020 | -321.15% |
| Sep 30, 2020 | -997.54% |
| Jun 30, 2020 | -1,277.04% |
| Mar 31, 2020 | -1,201.47% |